Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 9, 2011Clinical ProteomicsOpen Access

The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMichael J. DuffyNorth Carolina State UniversityMMMaeve MulloolyUniversity College DublinNONorma O’DonovanDublin City University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Duffy et al. (2011) studied this question.

synapsesocial.com/papers/6a84b24970882e11870cc94dhttps://doi.org/10.1186/1559-0275-8-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.1996 · 1,397 citations
  2. 2Anti–Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?2009 · 65 citations
  3. 3Inhibition of the Tumor Necrosis Factor-α-converting Enzyme by Its Pro Domain2004 · 117 citations
  4. 4The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion2003 · 733 citations
  5. 5Ectodomain shedding of the EGF‐receptor ligand epigen is mediated by ADAM172006 · 122 citations